Q-omics provides the consensus-scored FGF11 profile across patient tissues and cancer cell-line models. FGF11 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, FGF11 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, FGF11 RNA expression shows 17,347 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight KIRP, THCA, and DLBC as cancer lineages where FGF11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FGF11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FGF11 survival associations across molecular data types. FGF11 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FGF11 RNA expression–survival associations across cancer types. High FGF11 expression shows unfavorable associations in KIRP, UCEC, KICH and BLCA, but favorable associations in HNSC and ESCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for FGF11 RNA expression.
This table summarizes FGF11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for FGF11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FGF11 shows lower tumor expression in THCA, KICH and BRCA and higher tumor expression in LUSC, LUAD and BLCA. The THCA box plot shows higher FGF11 RNA expression in normal versus tumor tissue (log2 FC = −1.010, t-test p < 0.001).
This table shows molecular features associated with FGF11 in patient tissues and cancer cell lines. In patient samples, FGF11 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, FGF11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
